Search results
The Gold Rush for Weight Loss Drugs Is Here. These 3 Latecomers Could Be Worth a Buy.
Motley Fool via Yahoo Finance· 3 days agoAmgen is an established big pharma company with a massive pipeline and many avenues for growth...
Small Business - Cordele Dispatch | Cordele Dispatch
Cordele Dispatch· 6 days agoTruqap™ (capivasertib) plus fulvestrant now available in Canada Canada NewsWire MISSISSAUGA, ON, May 31, 2024 MISSISSAUGA, ON, May 31, 2024 /CNW/ - AstraZeneca is pleased ...
AbelZeta announces clinical data showing preliminary anti-tumor activity for C-CAR031, an armored...
Morningstar· 2 days agoCAR031 study at 9.03-mo median follow up achieves disease control rate (DCR) of 91.3% and objective response rate (ORR) of 56.5% for patients across all dose levels (DLs) and ORR of 75.0% at DL4 ROCKVILLE, Md., June 4, 2024 /PRNewswire/ -- AbelZeta
ASCO24: Enhertu aims to replace Herceptin in first-line metastatic breast cancer
Pharmaceutical Technology via Yahoo Finance· 4 days agoInterim safety and efficacy results of the Phase Ib/II Destiny-BREAST07 trial with Enhertu...
Some drugmakers to cap cost of asthma inhalers at $35 a month
NBC NEWS· 6 days agoStarting Saturday, the cost of inhalers will fall for many Americans, as new out-of-pocket price...
Cancer Drugs: Deals and Licensing for Antibody-Drug Conjugates | JD Supra
JD Supra· 9 hours agoAntibody-drug conjugates (ADCs) are a promising class of cancer treatments with an accelerating number of U.S. Food and Drug Administration (FDA) approvals and rapidly growing market size, as ...
Cramer's Lighting Round: ‘You've got a winner' with Astra Zeneca
NBC Los Angeles· 6 days ago“Mad Money” host Jim Cramer rings the lightning round bell, which means he’s giving his answers to...
Move over 'Magnificent 7,' the 'Fantastic 5' may offer higher earnings and return potential
CNBC· 5 hours agoLooking for a less risky way to find growth stocks amid all the artificial intelligence hype?...
Health Care Roundup: Market Talk
The Wall Street Journal· 7 days agoKeytruda is the world’s top-selling drug and raked in about $25 billion in revenue for Merck last year. (ben.glickman@wsj.com; @benglickman) 1151 ET – ...
Women denied ‘wonder drug’ that could double terminal breast cancer life expectancy
Daily Telegraph· 3 days agoWomen with HER2-low or ultra-low breast cancer who took Enhertu lived without their cancer growing...